The FDA has approved Awiqli, the first once‑weekly long‑acting basal insulin, for adults with type 2 diabetes, which offers ...

Hoogma RPLM et al. (2005) Comparison of the effects of continuous subcutaneous insulin infusion (CSII) and NPH-based multiple daily insulin injections (MDI) on ...

Please provide your email address to receive an email when new articles are posted on . You've successfully added to your alerts. You will receive an email when new content is published. Click Here to ...

A subcutaneous insulin-driven treatment protocol for diabetic ketoacidosis (DKA), instead of continuous intravenous insulin, can reduce intensive care unit (ICU) admission and hospital readmission in ...

A small device implanted just beneath the skin, roughly the size of a large postage stamp and weighing about two grams, kept ...

For over a century, scientists have chased the dream of insulin pills, but the digestive system kept destroying the drug ...

Overview: Insulin glargine is a long-acting insulin used to lower blood sugar levels in people with diabetes. It helps get sugar into your cells, so your body can use it for energy. The most common ...

Objective: Glycemic control using inhaled, dry-powder insulin plus a single injection of long-acting insulin was compared with a conventional regimen in patients with type 2 diabetes, which was ...

“Insulin injections remain a daily burden for many patients,” said Shingo Ito, an associate professor at Kumamoto University ...

“Insulin injections remain a daily burden for many patients,” said Associate Professor Shingo Ito. “Our peptide-based ...